IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
IGC PharmaIGC Pharma(US:IGC) Accessnewswire·2026-01-05 14:00
  • New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that it has entered into a Subscription Agreement (the "2025 SA") with a group of investors for the purchase and sale of an aggr ...